Acurx Pharmaceuticals reported net income of -$2.25M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.51M | 0.51M | 0.51M | 0.51M | 0.58M | 0.58M | 0.58M | 0.65M | 0.65M | 0.72M | 0.79M | 0.80M | 0.84M | 0.85M | 1.12M | 1.19M | 1.80M | 1.50M | 2.72M | 4.68M | ||||
| Operating items | ||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.13M | 0.72M | 0.82M | 0.91M | 1.59M | 1.43M | 1.02M | 1.74M | 1.35M | 1.94M | 1.56M | 1.83M | 1.20M | 0.83M | 0.60M | 0.52M | 0.43M | 0.28M | 0.34M | 1.07M | ||||
| Selling, General & AdministrativeSG&A | 3.52M | 1.91M | 1.85M | 1.71M | 1.95M | 1.83M | 1.89M | 1.71M | 1.77M | 3.17M | 2.82M | 2.30M | 1.63M | 1.97M | 1.58M | 1.75M | 1.60M | 1.34M | 1.37M | 1.24M | ||||
| Operating ExpensesOpex | 4.64M | 2.63M | 2.67M | 2.62M | 3.54M | 3.26M | 2.90M | 3.45M | 3.11M | 5.11M | 4.38M | 4.12M | 2.83M | 2.79M | 2.18M | 2.27M | 2.03M | 1.62M | 1.72M | 2.31M | ||||
| Operating IncomeOp. Inc | -4.12M | -2.83M | -2.79M | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M | -2.31M | |||||||||||||||
| EBIT | -4.12M | -2.83M | -2.79M | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M | -2.31M | |||||||||||||||
| Non-operating items | ||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 782.00 | 0.01M | 0.01M | 0.03M | 0.02M | 0.04M | 0.04M | 0.04M | 0.05M | |||||||||||||||
| Net income details | ||||||||||||||||||||||||
| EBT | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Profit After TaxPAT | -4.64M | -2.63M | -2.67M | -2.62M | -3.54M | -3.26M | -2.90M | -3.45M | -3.11M | -5.11M | -4.38M | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | ||||
| Income from Continuing OperationsIncome (Continuing) | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Net Income towards Common StockholdersNet Income | -4.12M | -2.82M | -2.78M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M | -2.25M | |||||||||||||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -5.21 | -3.45 | -3.44 | -2.15 | -1.89 | -1.23 | -1.05 | -0.62 | -0.53 | |||||||||||||||
| EPS (Diluted) | -5.21 | -3.45 | -3.44 | -2.15 | -1.89 | -1.23 | -1.05 | -0.62 | -0.53 | |||||||||||||||
| Shares Outstanding | 0.51M | 0.43M | 0.51M | 0.51M | 0.56M | 0.54M | 0.58M | 0.61M | 0.65M | 0.63M | 0.77M | 0.79M | 0.82M | 0.81M | 1.00M | 1.19M | 1.63M | 1.50M | 2.72M | 4.26M | ||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.51M | 0.43M | 0.51M | 0.51M | 0.56M | 0.54M | 0.58M | 0.61M | 0.65M | 0.63M | 0.77M | 0.79M | 0.82M | 0.81M | 1.00M | 1.19M | 1.63M | 1.50M | 2.72M | 4.26M | ||||
| EBITDA | -4.12M | -2.83M | -2.79M | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M | -2.31M |